eFFECTOR Therapeutics Virtual Investor R&D Day: Development Progress for Tomivosertib and Zotatifin, Including a Review of Phase 2 Data of Zotatifin in ER+ Metastatic Breast Cancer and Anticipated 2024 Milestones
About The Event
Join eFFECTOR Therapeutics for a virtual investor R&D day which will feature presentations by eFFECTOR management and Dr. Kevin Kalinsky, Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Glenn Family Breast Center at the Winship Cancer Institute.
Topics will include a summary of development progress for tomivosertib and zotatifin, a review of recently announced Phase 2 data of zotatifin in estrogen receptor-positive (ER+) metastatic breast cancer patients, potential market opportunities and competitive positioning of tomivosertib and zotatifin and a preview of expected 2024 catalysts.
A live question and answer session will follow the formal presentations.